Go­ing be­yond pro­tein degra­da­tion, a new Broad start­up kicks in­to gear to fix pro­tein func­tion­al­i­ty

There’s a pletho­ra of pro­tein degra­da­tion biotechs, and a small­er hand­ful of pro­tein sta­bi­liza­tion play­ers, but Lizzie Ngo was search­ing for some­thing more.

The prin­ci­pal at Long­wood Fund, the in­vest­ment firm be­hind the likes of Bi­cy­cle Ther­a­peu­tics, want­ed to know, “What else could we do be­yond just tar­get­ed pro­tein degra­da­tion?” she told End­points News.

While map­ping out the space, she and a col­league came across a 2020 pa­per from Amit Choud­hary’s lab at MIT and Har­vard’s Broad In­sti­tute. As so many biotechs’ ori­gin sto­ries be­gin, the pa­per led to a new start­up with am­bi­tions go­ing be­yond pro­tein degra­da­tion and sta­bi­liza­tion and in­to ac­ti­va­tion, in­ac­ti­va­tion and traf­fick­ing of pro­teins.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER